The Federal Trade Commission is coming out in support of legislation outlawing pay for delay deals between brand-name and generic drug manufacturers.

Pay for delay is where the drug maker that created a drug pays generic drug manufacturers not to make a generic equivalent once the patent has expired.

Eliminating this practice should save consumers about $35 billion over the next 10 years.